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Haemophilus influenzae is present as a commensal organism in the nasopharynx of most healthy adults from where
it can spread to cause both systemic and respiratory tract infection. This bacterium is divided into typeable forms
(such as type b) or nontypeable forms based on the presence or absence of a tough polysaccharide capsule.
Respiratory disease is predominantly caused by the nontypeable forms (NTHi). Haemophilus influenzae has evolved a
number of strategies to evade the host defense including the ability to invade into local tissue. Pathogenic
properties of this bacterium as well as defects in host defense may result in the spread of this bacterium from the
upper airway to the bronchi of the lung. This can result in airway inflammation and colonization particularly in
chronic obstructive pulmonary disease. Treatment of respiratory tract infection with Haemophilus influenzae is often
only partially successful with ongoing infection and inflammation. Improvement in patient outcome will be
dependent on a better understanding of the pathogenesis and host immune response to this bacterium.Review
Haemophilus influenzae was first identified by Pfeiffer in
1892, who (incorrectly) believed it was the cause of in-
fluenza [1]. It is an exclusively human pathogen and was
the first bacterium to have its genome completely
sequenced. This served as a precursor to the sequencing
of the human genome.
H. influenzae is a component of the normal upper re-
spiratory tract flora and is well recognized to be an im-
portant cause of systemic infection. It is also a major
cause of a variety of respiratory conditions and has had a
relatively low profile in this respect in comparison to
some other pathogens; such as Mycobacterium tubercu-
losis and Streptococcus pneumoniae.
Recently there has been increasing recognition that
this bacterium has a role in chronic lower respiratory
tract inflammation. However the interaction between H.
influenzae and the lung is still not well defined. A com-
bination of bacterial pathogenic features and deficiency
of host defense may permit this bacterium to establish
infection in the lower respiratory tract resulting inCorrespondence: paul.king@monash.edu
Department of Respiratory and Sleep Medicine and Department of Medicine,
Monash University, Monash Medical Centre, 246 Clayton Rd, Clayton,
Melbourne 3168, Australia
© 2012 King; licensee Springer. This is an Open
License (http://creativecommons.org/licenses/b
medium, provided the original work is properlyinflammation and clinical disease. This review will dis-
cuss the role of H. influenzae in the lower respiratory
tract in particular its role in bronchitis.Microbiology
Haemophilus influenzae is a gram-negative coccobacillus
with a variable shape (pleomorphic). It grows both aer-
obically and anaerobically. Aerobic growth requires the
presence of X (hemin) and V (nicotinamide adenine di-
nucleotide (NAD)) factors. In the laboratory it is classic-
ally grown on chocolate agar (Figure 1).
Haemophilus influenzae is divided into typeable and
nontypeable strains on the presence or absence of a
polysaccharide capsule. The typeable strains which have
this capsule are classified into six serotypes (designated
a to f) based on their ability to react with antisera
against recognized polysaccharide capsules [2,3]. The
type b form of H. influenzae (designated as Hib) is the
most prominent typeable form and its capsule is com-
posed of a linear ribosyl and ribotol phosphage polymer.
Nonencapulated forms are designated as nontypeable
Haemophilus influenzae (NTHi). The NTHi strains are
heterogeneous with a large number of different subtypes
[4] that can be demonstrated on electrophoresis of outer
membrane proteins or by enzymatic analysis. The NTHi
strains are the main cause of Haemophilus respiratoryAccess article distributed under the terms of the Creative Commons Attribution
y/2.0), which permits unrestricted use, distribution, and reproduction in any
cited.
Figure 1 Colonies of Haemophilus influenzae growing on a
chocolate agar plate.
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urease and ornithine decarboxylase.Epidemiology
Colonization of the upper respiratory tract with H.
influenzae begins in infancy. Approximately 20 % of
infants are colonized in the first year of life and this rises
progressively over time [5]. By the age of 5–6 years more
than 50 % of children will be colonized with this bacter-
ium and most healthy adults (at least 75 %) will be [1].
This is a dynamic process with turnover of different
strains. Children will have a strain for weeks to months,
which will then be cleared and the acquisition of a new
strain occurs [6]. Children will typically carry multiple
strains simultaneously whilst adults will be colonized
with only one strain [7].
This bacterium is spread by airborne droplets and con-
tact with secretions [8]. Children in day centers have a
particularly high incidence of infection and colonization
with H. influenzae. The acquisition of new strains may
be associated with acute exacerbations of airways disease
[9]. The number of times a child is colonized with differ-
ent isolates of NTHi is correlated with middle ear infec-
tion. The density of colonization is also a risk factor for
the development of middle ear infection; this has been
associated with lower levels of other commensal bacteria
such as Streptococcus viridans [10].
The recent widespread use of the H. influenzae type B
vaccine has caused a marked reduction in the prevalence
of clinical disease arising from type b H. influenzae in-
fection (from very common to rare). This has beenassociated with a proportionate decrease in the rate of
nasopharyngeal colonization.
Most healthy adults will have upper airway
colonization with H. influenzae. This process is dynamic
and the predominant strains are nontypeable. The naso-
pharynx serves as a potential reservoir of infection from
which this bacterium may spread to the lower respiratory
tract.
Pathogenesis
Haemophilus influenzae strains are divided into those
with a capsule (e.g. the type b form) or the non-
encapsulated strains (NTHi). The encapsulated strains
primarily have a role in systemic infection in conditions
such as meningitis. A principal defense against systemic
H. influenzae infection is antibody-mediated comple-
ment killing. Normal serum is bactericidal for most
strains of NTHi, but naturally-occurring bactericidal ac-
tivity for encapsulated bacteria is much less common,
particularly in children. In contrast NTHi strains rarely
cause disease outside the respiratory tract and can be
considered to be primary mucosal pathogens. The vast
majority of respiratory disease arises from the NTHi
strains. Important pathogenic mechanisms by which H.
influenzae establishes respiratory tract infection will now
be discussed in more detail.
Mucociliary interactions
The mucociliary apparatus is a first-line structural
defense against bacterial infection and H. influenzae
strains have a variety of mechanisms which can influence
its function. Outer membrane proteins such as P2 and
P5 facilitate binding of the bacteria to mucus [11,12].
Lipooligosaccharide (a lipopolysaccharide that lacks the
O-side chains and is abbreviated as LOS) is present in
the cell wall of NTHi strains and has a significant effect
on cilial function; Denny described that LOS produced
inhibition of ciliary function and loss/death of ciliary mu-
cosal cells [13]. Similar effects on ciliary function have
been described from protein D which is a lipoprotein
expressed on the surface of H. influenza [14].
Attachment to respiratory mucosa
A key step in pathogenesis is the ability to adhere to the
respiratory mucosa. NTHi appears to have a preference
for nonciliated cells or damaged mucosa. There are sev-
eral specific mechanisms which NTHi strains use to ad-
here to mucosa.
Adhesins
The adhesins are a common and important factor to fa-
cilitate epithelial attachment. These are present on a
large proportion of NTHi strains and share some hom-
ology with adhesins expressed by Bordatella pertussis
Figure 2 H. influenzae (stained with fluorescent dye) inside
macrophages.
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to NTHi infection [16]. A number of investigators have
demonstrated the importance of adhesins and there are
2 main subtypes HMW1 and HMW2 [17].
Pili
NTHi express pili which are rod-like projections on the
surface which cause agglutination of red blood cells and
attachment to respiratory tract epithelial cells [18].
There are 5 different types and these pili are present
only on a small subset of strains of NTHi [19-21].
Other factors
Approximately 25 % of NTHi strains lack adhesins/pili
but are still able to attach efficiently to respiratory epthi-
lium. Two other factors that are important are the Hia
and Hap proteins [22].
Evasion of mucosal immunity
After attachment to the mucosal surface, strains of
NTHi have a variety of different mechanisms which en-
hance persistence at the epithelial surface.
Proteases
Immunoglobulin (Ig) A is the main antibody subclass
that prevents epithelial infection. IgA binds to bacteria
and prevents mucosal attachment, inactivates toxins and
facilitates cytotoxicity. The predominant IgA subclass is
IgA1. NTHi secretes endopeptidases (Types 1 and 2),
which cleave and neutralize IgA1 [23,24]. Nearly all
NTHi strains express one of these IgA proteases which
are highly effective in inhibiting IgA.
Microcolony formation
St Geme et al have demonstrated the ability of NTHi to
form microcolonies on mucosal surfaces [8]. This prop-
erty is likely to inhibit the function of secreted bacterio-
static products such as lactoferrrin and lysozymes and
also potentially antibody function.
Phase variation/antigenic drift
Viruses such as influenza have well-documented abilities
to frequently change cell structures and this is a key fea-
ture in their pathogenesis. H. influenzae is also able to
lose or gain cell structures; a property called phase vari-
ation. Structures in which this occurs include LOS, adhe-
sins and pili. This ability has significant implications for
the function of antibodies and C-reactive protein [25].
In addition to phase variation, some strains of H. influ-
enzae undergo antigenic drift which involves permanent
change in amino acid sequences in some important im-
mune structures/epitopes. This is best described in the
context of the outer membrane protein P2 (which is
strongly immunogenic) [26]. Other examples of antigenicdrift involve P5 outer membrane protein and IgA1
proteases.Intracellular survival/invasion of local tissue
A potentially very important pathogenic feature of
Haemophilus influenzae is its ability to invade local tissue
and survive intracellularly in the respiratory tract. This
has been described in the context of nontypeable strains.
The main cells targeted by NTHi appear to be macro-
phages and epithelial cells. There have been a number of
studies which have demonstrated the in-vitro ability of
NTHi to survive inside these cells for at least 72 hours
[27-30]. An example of NTHi inside macrophages is
shown in Figure 2.
Two early studies demonstrated the presence of NTHi
between the epithelial cells of patients with chronic bron-
chitis and adenoidal inflammation [30,31]. Electron mi-
croscopy showed the disruption of intracellular junctions
and the presence of bacteria between cells and in the
phagocytic vacuoles of mononuclear cells. Forsgren et al
demonstrated the presence of viable NTHi in mono-
nuclear and epithelial cells obtained from children who
had adenoid tissue resected as part of standard treatment
[32].
Moller et al demonstrated extensive invasion of lung
explants from patients with end-stage lung disease
(including COPD and cystic fibrosis) with H. influenza;
the organism was present in the epithelium, the sub-
mucosa of the bronchi, the bronchioles, the interstitium,
and the alveolar epithelium in over half of the subjects
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H. influenzae in lung tissue in 40 % of subjects in all
stages of COPD [34]. Another study found very high
levels of intracellular NTHi present in subjects who had
had exacerbations of COPD [35].
Haemophilus influenzae has a number of mechanisms
that allow it to persist in the human host. The ability to be
able to invade into lung tissue may be particularly import-
ant in the pathogenesis of this bacterium. Key mechan-
isms are summarized in Table 1.
Immune response
NTHi is present in the nasopharynx of most healthy
adults but only causes clinical disease in a minority of
subjects it infects. Therefore the nature of the respira-
tory tract immune/inflammatory response may be very
important in the pathogenesis of this bacterium. NTHi
causes strong stimulation of both innate and adaptive
immunity.
Innate immune responses
Innate immunity serves as the first-line of defense
against infection and is comprised of both structural and
cellular defenses.
Structural defenses have a number of components in-
cluding cough, barrier function and the mucociliary ap-
paratus. Impairment of mucocilary function as occurs in
cystic fibrosis and immotile cilia syndrome, is associated
with lung H. influenzae infection.
The cellular innate immune response is a rapidly
evolving area. It is mediated by neutrophils and particu-
larly macrophages, which recognize bacterial pathogens
by toll-like receptors (TLRs). The outer membrane
proteins of H. influenzae such as P2 and P6 strongly
activate innate immunity. P6 activates macrophages to
produce interleukin (IL) 8 and tumor necrosis factor alpha
(TNF-α) [36,37]. P6 is also important for the migration
of dendritic cells. NTHi lysate (i.e. killed/inactivatedTable 1 Important pathogenic features of nontypeable
Haemophilus influenzae
Mucociliary interactions Binding to mucus















phagocytes and epithelial cells
Extensive invasion of lung parenchymabacteria) upregulates the production of nuclear tran-
scription factor-kappa β (NF-κβ), which is a key driver
of inflammation [38]. Epidermal growth factor receptor
(EGFR) has also recently been shown to be important in
NF-κβ activation [39].
The NF-κβ pathway is principally activated through
toll-like receptors (TLRs) which function as pattern
receptors (e.g. for bacterial motifs). Activation of TLRs by
bacterial motifs drives an inflammatory response, which is
designed to clear infection. Both TLR-2 and TLR-4 have
been shown to be important in immune responses to
NTHi [40,41].
TLR-4 primarily recognizes lipopolysaccharide (LPS) a
component of the gram-negative cell wall. NTHi has
lipooligosaccharide (LOS), which is very similar to LPS
but lacks O-antigen units. Activation of TLR4 results in
the production of a variety of inflammatory mediators
by the macrophage, which have a key role in initiating
innate immunity.
TLR-2 is also expressed on the surface of innate and
immune cells. Outer membrane P6 activates TLR-2 with
up-regulation of NF-κβ and the production of inflamma-
tory mediators.
Adaptive immune responses
The adaptive immune response develops after the innate
response and is particularly important in chronic infec-
tious disease. It is primarily mediated by B lymphocytes
(humoral immunity) and T lymphocytes (cellular
immunity).
Studies have demonstrated that the great majority of
healthy subjects and those with chronic airways disease
have strong antibody responses to NTHi. It has also
been shown that complement is bactericidal for NTHi.
Antibody causes activation of the terminal attack com-
plex of complement and this is very effective in killing
NTHi [42]. This mechanism may explain why NTHi is
primarily a mucosal pathogen that rarely spreads beyond
the respiratory tract in contrast to the typeable forms
such as Hib which are protected by the tough polysac-
charide capsule and frequently cause systemic disease.
Hypogammaglobulinaemia has been shown to be an im-
portant risk factor for systemic infection with NTHi.
T cells have a key role in the protection against intra-
cellular infection. Both T helper (Th) cells and cytotoxic
T (CTL) cells secrete cytokines (which drive inflamma-
tion) and produce cytotoxic mediators. The ability of T
cells to proliferate to NTHi stimulation influences clin-
ical disease. Patients with obstructive airways disease
have deficient T-cell responses to NTHi when compared
to healthy controls specifically; 1), decreased Th1 cell
function, particularly production of interferon gamma
(IFN-γ) & CD40 ligand (CD40L) [43] and 2), decreased
CTL cell function, particularly production of IFN-γ [44].
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the addition of IFN-γ & CD40L [45]. A recent study has
confirmed that Th1 cell responses to NTHi in COPD
are deficient [46] and TLRs appear to be important in
this mechanism.
There are two other important situations, which have
potentially significant effects on the immune response to
NTHi in the lung. They are cigarette smoke and viral
infections. These will now be discussed in more detail.
Effect of cigarette smoking on the lung immune response
Cigarette smoking is the key risk factor for the develop-
ment of COPD and has a significant effect on the lung
immune response [47]. Smoking directly damages the
respiratory epithelium and inhibits mucociliary function
[48,49]. It has a wide variety of effects on alveolar
macrophages, dendritic cells and lymphocytes which in-
hibit the ability of the lung to clear infection [47]. Smok-
ing has been found to be associated with increased lung
inflammation following challenge with NTHi [50].
Interaction between viral infection and Haemophilus
influenzae
In clinical practice there is a frequent association be-
tween viral infection and bacterial infection. In the con-
text of H. influenzae infection the two best-described
associations have been with 1), epidemic influenza and
2), rhinovirus.
Exacerbations of COPD are frequently associated with
combined viral and bacterial infection and the most
common co-infection is the combination of rhinovirus
and H. influenzae, which is also associated with
increased severity of exacerbations [51,52]. There is pre-
liminary evidence from laboratory studies that rhinovirus
may interact with NTHi. Rhinovirus suppresses host
macrophage interleukin 1 responses to NTHi [53] and
enhances migration of NTHi across epithelial cells [54].
A major cause of death in epidemic viral influenza is
secondary bacterial lung infection. Outbreaks are asso-
ciated with different bacterial infections. The “Spanish
flu” outbreak following World War 1 was associated
with a high incidence of H. influenzae infection [55,56].
Viral influenza causes significant damage to the respira-
tory epithelial barrier and this may be an important
mechanism of secondary bacterial infection.
Clinical features
Infection of the lower respiratory is predominantly by the
nontypeable strains of Haemophilus influenzae (NTHi).
The dominant manifestation is bronchitis, which may be
acute or chronic and has been well described in the con-
text of COPD, bronchiectasis and cystic fibrosis. Exacer-
bations are an important feature of these forms of
bronchitis and are characterized by episodes of acuteclinical deterioration usually in association with increased
airway inflammation. Additionally this bacterium is also a
major cause of pneumonia.Chronic obstructive pulmonary disease
COPD is a major health problem and the fourth leading
cause of mortality worldwide. It is characterized by the
presence of airway inflammation that is most pro-
nounced in the bronchial wall. This bronchial wall in-
flammation persists despite the cessation of smoking.
The most common cause of chronic bacterial airway
colonization in patients with COPD is NTHi accounting
for up to half of all isolates [35,57-60]. The major bacter-
ial cause of exacerbations of COPD is NTHi, 25 to over
80 % of exacerbations are associated with H. influenzae
[35,57-59]. In addition the bacterial load of NTHi in lung
airways has been shown to contribute to airway inflam-
mation in stable chronic bronchitis [61]. Colonization
with NTHi is associated with more severe COPD exacer-
bations [62].
Exacerbations of COPD from NTHi can arise from the
acquisition of new strains [9](presumably from the upper
airway) or from existing colonizing strains.
The exact role of NTHi in the inflammatory process
is still not well defined but it is possible that NTHi may
invade into the bronchial wall to activate T cells and
contribute to inflammation. A murine model of COPD
has recently demonstrated that the addition of an NTHi
lysate induces the formation of lymphoid follicles in the
bronchi [63].Bronchiectasis and cystic fibrosis
Bronchiectasis is characterized by persistent bacterial in-
fection that causes lung damage and also results in
chronic airflow obstruction [64]. The bacterial infection
generally appears to result as a consequence of a defect
in host defense which results in chronic bacterial airway
infection. The dominant bacterium in bronchiectasis is
NTHi and this is a major driver of lung inflammation.
There is considerable overlap between bronchiectasis
and COPD.
The principal manifestation of cystic fibrosis (CF) is
severe and progressive bronchiectasis, which results in
respiratory failure. It is thought that a defect in muco-
ciliary function (through the cystic fibrosis transmem-
brane conductance regulator (CFTR) gene) results in
progressive airway infection. NTHi is prominent in the
early stages of CF; in later stages other bacterium such
as Pseudomonas are predominant. However Moller et al
described H. influenzae to be the dominant bacterium in
the lung parenchyma of explants from CF patients.
Therefore in the later stages of CF NTHi may still be
important in parenchymal lung infection.
Figure 4 Computed tomography scan taken of a patient with a
lung abscess that required surgical removal. H. influenzae was
isolated from the lung tissue.
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NTHi is also one of the leading causes of pneumonia in
adults (with Streptococcus pneumoniae and Moxarella
catarrhalis). Most patients with NTHi pneumonia have
bronchopneumonia with cough, fever and systemic
upset. The illness is generally less fulminant than that
with S. pneumoniae and commonly occurs in patients
with underlying lung disease (particularly COPD).
Two examples of patients with H. influenzae infection
are shown in Figures 3 and 4.
Possible role of NTHi in lung cancer
Smoking is the primary risk factor for both chronic ob-
structive pulmonary disease (COPD) and lung cancer.
Only a minority of smokers develop COPD and the
presence of COPD has been demonstrated to be an im-
portant risk factor (independent of the risk of smoking)
in the development of lung cancer. It has been specu-
lated that NTHi-driven inflammation in the context of
COPD may be a risk factor for the development of lung
cancer [65].
There have been several mechanisms described which
may suggest a role for NTHi-driven inflammation as a
risk factor for lung cancer. NTHi activates proliferative
and antiapoptotic pathways [38,66] and promotes lung
cancer in a Clara cell-targeted mouse model of lung can-
cer [67]. Interleukin-6 and Il-17 generated in response
to NTHi may be important risk factors as well.
Treatment
Treatment of Haemophilus influenzae infection should
be straightforward as this bacterium is usually sensitive to
most standard antibiotics. In practice though treatment isFigure 3 Computed tomography (CT) scan of a subject with
severe lower lobe bronchiectasis and recurrent isolation of
H. influenzae from sputum.often only partially successful with recurrent/non-
clearing infection. Particularly in the context of chronic
bronchitis (e.g. as in COPD and bronchiectasis) NTHi
often appears to have established a niche in the airway,
which makes it relatively resistant to chemotherapy.
Use of antibiotics
Oral antibiotics such as β-lactams are appropriate first-
line therapy for most patients. A proportion of H. influ-
enzae isolates produce β-lactamase (this varies markedly
between different locations) and in this circumstance,
extended spectrum cephalosporins, amoxicillin-clavulinic
acid, trimethoprim-sulfamethoxazole, tetracyclines, qui-
nolones and macrolide antibiotics are appropriate thera-
peutic choices. In Spain and Japan, β-lactamase negative,
ampicillin-resistant (BLNAR) strains are prevalent. These
BLNAR strains are associated with a high incidence of
pneumonia [68,69]. For hospitalized patients particularly
if there is associated respiratory failure the parenteral
route of administration may be preferred.
For patients who have repeated isolation of H. influen-
zae despite the use of appropriate antibiotics consider-
ation should be given to the use of longer-term
antibiotics or those with good intracellular penetration.
As discussed previously NTHi has the ability to live
intracellularly and thus be protected from a number anti-
biotics particularly the β-lactams [70]. Agents with good
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and quinolones. In the author’s experience, longer
courses of antibiotics with good intracellular penetration
may be helpful (although this has potential issues of
resistance).
Vaccination
The vaccine to type B encapsulated H. influenzae
induces humoral immunity to the capsule and has been
highly effective in reducing the incidence of disease from
this pathogen. This vaccine is now standard for childrenFigure 5 The potential spread of nontypeable strains of
H. influenzae (NTHi) into the lung. A), Most healthy subjects have
nasopharyngeal colonization with NTHi. A combination of bacterial
pathogenic mechanisms and defects in host defense may allow
NTHi to move down into the lower respiratory tract B). In the
bronchi, NTHi may cause acute exacerbations of airway disease
and/or chronic colonization. C), The bacterium may invade into
bronchial cells such as macrophages or epithelial cells or D), may
in more advanced lung disease invade into the parenchyma.in industrialized countries. Vaccination is usually given
at 2 months, 6 months and 12–15 months.
In contrast to Hib vaccination for NTHi strains is not
well established. NTHi infection occurs from a wide var-
iety of different and very heterogeneous strains and the
protective immune response has not been clearly
defined. There have been a number of published studies
measuring the effect of vaccination in animal models. A
major problem with the use of animal models is that
NTHi is an exclusively human pathogen, which generally
does infect animals well.
An oral vaccine consisting of multiple strains of killed
NTHi has been used with some reduction in exacerba-
tions [71]. More recently 2 trials of a new form of oral
NTHi vaccine have demonstrated a reduction in exacer-
bations [72,73]. Subjects were given 3 doses of inacti-
vated NTHi on a monthly basis with changes in the
expression of T cell responses and specific immuno-
globulin production.Conclusions
H. influenzae is present in the nasopharynx of most
healthy adults. Defects in host defense and pathogenic
mechanisms of the bacteria may result in migration into
the lower respiratory tract. This results in bronchitis,
which may be acute or chronic. Invasion into respiratory
tract cells, the bronchial wall and parenchyma of the
lung may then occur. This process is summarized in
Figure 5.
This bacterium is increasingly being recognized as a
major cause of chronic infection/inflammation in the
context of COPD. In the author’s opinion the establish-
ment of H. influenzae infection in the airway may lead
to a self-perpetuating inflammatory process that has a
major role in the development of airway obstruction.
Better understanding of the pathogenesis of Haemophi-
lus influenzae in the respiratory tract is likely to lead to
more effective treatment; in particular the use of
vaccination.
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